Literature DB >> 14714897

The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12.

Christopher N Scanlan1, Ralph Pantophlet, Mark R Wormald, Erica Ollmann Saphire, Daniel Calarese, Robyn Stanfield, Ian A Wilson, Hermann Katinger, Raymond A Dwek, Dennis R Burton, Pauline M Rudd.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14714897     DOI： 10.1007/978-1-4615-0065-0_13

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  33 in total

Review 1.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

2.  The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12.

Authors:  Antoine Chaillon; Martine Braibant; Thierry Moreau; Suzie Thenin; Alain Moreau; Brigitte Autran; Francis Barin
Journal:  J Virol       Date:  2011-01-19       Impact factor: 5.103

3.  Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.

Authors:  Jean-Philippe Julien; Nerea Huarte; Rubén Maeso; Stefka G Taneva; Annie Cunningham; José L Nieva; Emil F Pai
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

4.  Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).

Authors:  Rajesh Ringe; Jayanta Bhattacharya
Journal:  Ther Adv Vaccines       Date:  2013-07

5.  Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.

Authors:  D Noah Sather; Sara Carbonetti; Delphine C Malherbe; Franco Pissani; Andrew B Stuart; Ann J Hessell; Mathew D Gray; Iliyana Mikell; Spyros A Kalams; Nancy L Haigwood; Leonidas Stamatatos
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

6.  Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus.

Authors:  Jan Balzarini; Kristel Van Laethem; Dirk Daelemans; Sigrid Hatse; Antonella Bugatti; Marco Rusnati; Yasuhiro Igarashi; Toshikazu Oki; Dominique Schols
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

7.  Antigenic properties of the HIV envelope on virions in solution.

Authors:  Krishanu Ray; Meron Mengistu; Lei Yu; George K Lewis; Joseph R Lakowicz; Anthony L DeVico
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

Review 8.  Progress towards recombinant anti-infective antibodies.

Authors:  Jennifer C Pai; Jamie N Sutherland; Jennifer A Maynard
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2009-01

9.  Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition.

Authors:  Milan Raska; Kazuo Takahashi; Lydie Czernekova; Katerina Zachova; Stacy Hall; Zina Moldoveanu; Matt C Elliott; Landon Wilson; Rhubell Brown; Dagmar Jancova; Stephen Barnes; Jana Vrbkova; Milan Tomana; Phillip D Smith; Jiri Mestecky; Matthew B Renfrow; Jan Novak
Journal:  J Biol Chem       Date:  2010-05-03       Impact factor: 5.157

10.  Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization.

Authors:  Emma T Crooks; Pengfei Jiang; Michael Franti; Sharon Wong; Michael B Zwick; James A Hoxie; James E Robinson; Penny L Moore; James M Binley
Journal:  Virology       Date:  2008-06-09       Impact factor: 3.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.